- FY 2023 Annual Report (2023)
- Federal Trade Commission Report on Pharmaceutical Product Hopping (2022) ( )
- Summary Report on the FDA/FTC Workshop on a Competitive Marketplace for Biosimilars (2023) ( )
- State Restrictions on Vision Care Providers: The Effects on Consumers ("Eyeglasses II") (1980) ( )
- Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers ( )
- Order to File Special Report to Collect Information Regarding Certificates of Public Advantage (COPA) ( )
- Prices for Medical Services Vary Within Hospitals, But Vary More Across Them ( )
- Simulating Hospital Merger Simulations ( )
- The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes ( )
- Why is Distance Important for Hospital Choice? Separating Home Bias from Transport Costs ( )
- Price Effects of a Merger: Evidence from a Physicians’ Market ( )
- Direct-to-Consumer Advertising and Online Search ( )
- Ophthalmic Practice Rules: State Restrictions On Commercial Practice: "Eyeglasses II": Report of the Staff to the Federal Trade Commission and Recommendation on Proposed Trade Regulation Rule: 16 CFR Part 456: Bureau of Consumer Protection ( )
- Hearing Aid Industry Staff Report: Reanalysis of the Rulemaking Record and Revised Recommendation That the Commission Promulgate A Revised Trade Regulation Rule: Bureau of Consumer Protection ( )
- Report of the Presiding Officer on the Proposed Trade Regulation Rule For the Hearing Aid Industry ( )
- Staff Report on Drug Product Selection ( )
- Competition in the Pet Medications Industry: Prescription Portability and Distribution Practices ( )
- Agreements Filled With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed In Fiscal Year 2013: A Report By the Bureau of Competition ( )
- Banning Foreign Pharmacies from Sponsored Search: The Online Consumer Response ( )
- Self-Regulation in the Alcohol Industry: Report of the Federal Trade Commission ( )
- Policy Perspectives: Competition and the Regulation of Advanced Practice Nurses ( )
- Economics at the FTC: Physician Acquisitions, Standard Essential Patents, and Accuracy of Credit Reporting ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2011: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2010: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2009: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2008: A Report by the Bureau of Competition ( )
- Emerging Health Care Issues: Follow-On Biologic Drug Competition: A Federal Trade Commission Report ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2007: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2006: A Report by the Bureau of Competition ( )